dipyridamole and montelukast

dipyridamole has been researched along with montelukast in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (66.67)24.3611
2020's2 (33.33)2.80

Authors

AuthorsStudies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ1
Ekins, S; Williams, AJ; Xu, JJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Ma, C; Wang, J1
Huang, YY; Li, Z; Lin, Y; Liu, R; Luo, HB; Wang, X; Zhan, CG1

Reviews

1 review(s) available for dipyridamole and montelukast

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

5 other study(ies) available for dipyridamole and montelukast

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Developing structure-activity relationships for the prediction of hepatotoxicity.
    Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes

2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors.
    Proceedings of the National Academy of Sciences of the United States of America, 2021, 02-23, Volume: 118, Issue:8

    Topics: Acetates; Atazanavir Sulfate; Benzimidazoles; Biphenyl Compounds; Chloroquine; COVID-19 Drug Treatment; Cyclopropanes; Dipyridamole; Humans; Oxytetracycline; Pharmaceutical Preparations; Protease Inhibitors; Quinolines; SARS-CoV-2; Sulfides; Tetrazoles

2021
Reply to Ma and Wang: Reliability of various in vitro activity assays on SARS-CoV-2 main protease inhibitors.
    Proceedings of the National Academy of Sciences of the United States of America, 2021, 02-23, Volume: 118, Issue:8

    Topics: Acetates; Atazanavir Sulfate; Benzimidazoles; Biphenyl Compounds; Chloroquine; COVID-19 Drug Treatment; Cyclopropanes; Dipyridamole; Humans; Oxytetracycline; Protease Inhibitors; Quinolines; Reproducibility of Results; SARS-CoV-2; Sulfides; Tetrazoles

2021